Sign in
WithdrawnPhase 1/2

Imaging with [89Zr]Panitumumab-PET/MRI in Patients with Newly Diagnosed Colorectal Cancer

Key facts

Who runs it
University of Alabama at Birmingham
Trial code
Status
Withdrawn
Phase
Phase 1/2
Started
14 Mar 2019
Ended
Jan 2026
Type of study
Interventional
Treatments tested
  • [89Zr]Panitumumab PET-MRI
Record updated
31 January 2025
Why it stopped
Study was not able to enroll any subjects

Who can take part

Age
19 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Be at least 19 years of age
  • Diagnosis of colon cancer
  • Scheduled to undergo surgical resection

Who cannot take part

  • Contraindication for MRI study (e.g. non-removable metal implants or certain tattoos)
  • Allergy to contrast imaging agents
  • Inability to provide informed consent
  • Pregnancy
  • Inability to lie still for the imaging study
  • Weight over 350 lbs., due to the scanner bore size
  • Inability to receive Omnipaque (iohexol) iodinated contrast
  • Inability to receive glucagon
  • Inability to receive Eovist (gadoxetate disodium) gadolinium based contrast agent
  • Finding or suspicion of distant metastases on CT

About the trial

What the trial wants to find out

This clinical study will investigate the utility of PET imaging with [89Zr]Panitumumab for imaging of EGFR expression in newly diagnosed colon cancer patients to assess lymph node involvement. If promising, this data will be used to design larger trials.

The group in the trial

  • [89Zr]Panitumumab-PET/MRI patientsTreatment being tested

    All study patients will receive \[89Zr\]Panitumumab-PET/MRI imaging.

    Treatment: [89Zr]Panitumumab PET-MRI

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
31 January 2025